Source link : https://www.newshealth.biz/health-news/biontechs-cancer-drug-meets-primary-endpoint-in-phase-2-trial/
(Reuters) – COVID-19 vaccine maker BioNTech’s cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday. The trial met its primary endpoint, with data demonstrating a statistically significant improvement in the overall response rate in patients treated with […]
Author : News Health
Publish date : 2024-07-30 10:52:53
Copyright for syndicated content belongs to the linked Source.
Categories